AT 300 - Akashi Therapeutics/State University of New York at Buffalo
Alternative Names: AT-300; GsMtx-4Latest Information Update: 10 Mar 2023
At a glance
- Originator State University of New York
- Class Antiarrhythmics; Peptides
- Mechanism of Action Calcium channel antagonists; Ion channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
- No development reported Atrial fibrillation
Most Recent Events
- 10 Mar 2023 Preclinical development in Duchenne muscular dystrophy is ongoing in USA
- 28 Oct 2018 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA
- 15 Sep 2014 Akashi Therapeutics licenses global development and commercialisation rights for GsMtx 4 for Duchenne muscular dystrophy